Latest News

Boehringer begins enrolment in Phase III trial of nintedanib for fibrosing lung diseases

US-based Boehringer Ingelheim Pharmaceuticals has begun patient enrolment in the Phase III progressive fibrosing interstitial lung disease (PF-ILD) clinical trial of nintedanib to treat...

Boehringer begins enrolment in Phase III trial of nintedanib for fibrosing lung diseases

M&As this week: Nivalis Therapeutics, Medidata Solutions

Nautilus Merger Sub, a subsidiary of US-based pharmaceutical company, Nivalis Therapeutics, has reached a reverse takeover agreement to acquire Alpine Immune...

M&As this week: Nivalis Therapeutics, Medidata Solutions

Clearside concludes enrolment in Phase I/II trial of CLS-TA to treat DME

US-based biopharmaceutical firm Clearside Biomedical has concluded patient enrolment in the exploratory Phase I/II HULK trial of CLS-TA to treat diabetic macular edema...

Clearside concludes enrolment in Phase I/II trial of CLS-TA to treat DME

Deals this week: Galapagos, Bristol-Myers Squibb, Zymeworks

Belgium-based clinical-stage biotechnology company Galapagos has announced the pricing for its proposed offering of American depository shares (ADS) to raise funds for its general...

Deals this week: Galapagos, Bristol-Myers Squibb, Zymeworks

Lion Biotechnologies and MD Anderson to investigate TIL therapy in solid tumour trials

Lion Biotechnologies has entered a multi-year strategic alliance agreement with the University of Texas MD Anderson Cancer Center to investigate its tumour-infiltrating lymphocyte (TIL) therapy...

Lion Biotechnologies and MD Anderson to investigate TIL therapy in solid tumour trials

Abide doses first patient in Phase Ib trial of ABX-1431 to treat tourette syndrome

US-based Abide Therapeutics has started dosing patients in a Phase Ib clinical trial of ABX-1431 for the treatment of tourette syndrome (TS)....

Abide doses first patient in Phase Ib trial of ABX-1431 to treat tourette syndrome

Bavarian Nordic commences Phase II combination trial for prostate cancer

Danish-based biotechnology firm Bavarian Nordic has commenced a Phase II clinical trial of Prostvac (rilimogene) in combination with Yervoy (ipilimumab) and / or Opdivo (nivolumab) to...

Bavarian Nordic commences Phase II combination trial for prostate cancer

AbbVie's veliparib fails to meet primary endpoints in two Phase III combination trials

AbbVie's veliparib fails to meet primary endpoints in two Phase III combination trials

GeNeuro starts Phase IIa trial of GNbAC1 in Australia to treat Type 1 diabetes

Swiss-based GeNeuro has started a Phase IIa clinical trial of GNbAC1 in Australia for the treatment of Type 1 diabetes (T1D)...

GeNeuro starts Phase IIa trial of GNbAC1 in Australia to treat Type 1 diabetes

Novartis and Allergan to conduct Phase IIb trial to treat NASH

Swiss healthcare firm Novartis has entered a clinical trial agreement with Irish pharmaceutical company Allergan to conduct a Phase IIb trial of FXR agonist and cenicriviroc (CVC) combination...

Novartis and Allergan to conduct Phase IIb trial to treat NASH

Immunovaccine starts dosing in Phase Ib/II trial of DPX-E7 to treat HPV-related cancers

Immunovaccine starts dosing in Phase Ib/II trial of DPX-E7 to treat HPV-related cancers

OncoMed's tarextumab fails to meet endpoints in Phase II trial for small-cell lung cancer

OncoMed's tarextumab fails to meet endpoints in Phase II trial for small-cell lung cancer

Medicenna begins dosing in Phase IIb trial of MDNA55 to treat rGB

Medicenna Therapeutics' subsidiary Medicenna BioPharma has begun dosing patients in the Phase IIb trial of its MDNA55 to treat recurrent glioblastoma...

Medicenna begins dosing in Phase IIb trial of MDNA55 to treat rGB

Genentech reports positive interim data from Phase III trial of emicizumab for haemophilia A

Roche's biotechnology subsidiary Genentech has reported positive interim results from the Phase III HAVEN 2 clinical trial of emicizumab for the treatment of children with haemophilia A...

Genentech reports positive interim data from Phase III trial of emicizumab for haemophilia A

Deals this week: Axovant Sciences, Ferring International, Takeda Pharmaceutical Company

Axovant Sciences has announced an equity offering to raise $100m in gross proceeds, along with a 30-day option to underwriters to purchase up to an additional $15m worth of its common stock...

Deals this week: Axovant Sciences, Ferring International, Takeda Pharmaceutical Company

Themis begins Phase I trial of MV-ZIKA-101 against Zika virus

Themis begins Phase I trial of MV-ZIKA-101 against Zika virus

Transgene starts Phase II trial of Pexa-Vec and cyclophosphamide for breast cancer and STS

French-based biotechnology firm Transgene has started dosing patients in the Phase II stage of the METROmaJX clinical trial of Pexa-Vec and metronomic cyclophosphamide combination for the...

Transgene starts Phase II trial of Pexa-Vec and cyclophosphamide for breast cancer and STS

BMS and Apexigen to assess Opdivo + APX005M combination for NSCLC

Bristol-Myers Squibb (BMS) has entered a clinical collaboration with biopharmaceutical firm Apexigen to assess the combination of Opdivo (nivolumab) with APX005M for the treatment of advanced...

BMS and Apexigen to assess Opdivo + APX005M combination for NSCLC

Rebiotix's RBX2660 demonstrates positive outcome in Phase II trial for C. diff. infection

Rebiotix's RBX2660 demonstrates positive outcome in Phase II trial for C. diff. infection

Alexo starts dosing in Phase I trial of ALX148 to treat solid tumours and lymphoma

Immuno-oncology company Alexo Therapeutics has started dosing patients in the Phase I clinical trial of a fusion protein ALX148 for the treatment of solid tumours and...

Alexo starts dosing in Phase I trial of ALX148 to treat solid tumours and lymphoma

Inotek closes enrolment in Phase II trial of trabodenoson + latanoprost for glaucoma

Inotek Pharmaceuticals has closed patient enrolment in the Phase II clinical trial of fixed-dose combination (FDC) of trabodenoson and latanoprost to treat patients with glaucoma....

Inotek closes enrolment in Phase II trial of trabodenoson + latanoprost for glaucoma
cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1460672566_rd1460672566_371857150_ap1460672566_1857678299_1016278895